期刊文献+

药师在药物相关性颌骨坏死患者临床诊疗及监护中的作用 被引量:3

Role of clinical pharmacists in clinical diagnosis and treatment for patients with bisphosphonate-related osteonecrosis of the jaw
下载PDF
导出
摘要 临床药师通过参与3例临床双膦酸盐类药物致颌骨坏死(BRONJ)患者的诊疗过程,进行药学问诊,协助医师及时判断确诊病因,避免出现误诊、漏诊,也分析了如何根据患者伴发疾病的情况进行双膦酸盐药物治疗方案的调整,为如何帮助患者制定更合理、有效、有针对性的联合用药方案提供了思路。医师采纳临床药师的建议后,进行了双膦酸盐治疗方案的调整;临床药师也为患者如何继续药物治疗进行了宣教。患者通过治疗,情况好转出院,门诊随访。在BRONJ患者的临床诊疗过程中,临床药师对可能发生的BRONJ进行判断,参与双膦酸盐治疗方案的调整,与医师进行了良好而有效的沟通,并给予医师相应的建议,为临床安全、合理和有效的药物治疗提供了一定的参考。 This paper explores the role of clinical pharmacists in the clinical diagnosis and treatment of patients with bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clinical pharmacists participated in the therapy for 3 patients with BRONJ, helped surgeons to diagnose BRONJ through pharmacologic inquiry, suggested changes and substitution treatments of bisphosphonate. Oral surgeons adopted the suggestions of the clinical pharmacist, and the patient was recovered and discharged ouring to clinical pharmacist's participation in the drug therapy, and individualized therapy to ensure safe and rational use of drugs.
作者 潘姝 原永芳 金剑 PAN Shu;YUAN Yong-fang;JIN Jian(Department of Pharmacy,Shanghai Ninth People's Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200011)
出处 《中南药学》 CAS 2018年第9期1318-1321,共4页 Central South Pharmacy
关键词 颌骨坏死 双膦酸盐 唑来膦酸 帕米膦酸 临床药师 osteonecrosis of the jaw bisphosphonate zoledronic acid pamidronic acid clinical pharmacist
  • 相关文献

参考文献4

二级参考文献98

  • 1阮敏,季彤,张陈平.双膦酸盐性颌骨坏死的研究进展[J].上海口腔医学,2006,15(6):663-667. 被引量:6
  • 2Sawatari Y, Marx RE. Bisphosphonates and bisphosphonate induced osteonecrosis [J]. Oral Maxillofacial Surg Clin North Am, 2007,19(4):487-498.
  • 3Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic[J]. J Oral Maxillofac Surg,2003,61 (9): 1115-1118.
  • 4Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases[J]. J Oral Maxillofae Surg, 2004,62(5):527-534.
  • 5ASBMR task force on bisphosphonate-associated ONJ. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research[J]. J Bone Miner Res,2007,22(10): 1479-1491.
  • 6Advisory Task Force On Bisphosphonate-Related Osteonecrosis of the Jaws,American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws [J].J Oral Maxillofac Surg,2007,65(3):369-376.
  • 7Monkkonen H, Auriola S, Lehenkari P, et al. A new endogenous ATP analog(ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogencontaining bisphosphonates[J]. Br J Pharmacol,2006,147 (4):437-445.
  • 8Sedghizadeh PP, Stanley K, Caligiuri M, et al. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry[J]. J Am Dent Assoc,2009,140(1):61-66.
  • 9Almazrooa SA, Woo SB. Bisphosphonate and nonbisphosphonateassociated osteonecrosis of the jaw[J]. J Am Dent Assoc,2009,140 (7):864-875.
  • 10Abu-ld MH, Wamke PH, Gottschalk J, et al. "Bis-phossy jaws" -high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw[J]. J Craniomaxillofac Surg, 2008,36(2):95- 103.

共引文献20

同被引文献10

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部